# PIK3R2

Source: https://onco.cc/targets/pik3r2/  
OnCo record `pik3r2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PIK3R2 (Phosphatidylinositol 3-kinase regulatory subunit beta) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.

## Summary

Regulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signalling cascades involved in cell growth, survival, proliferation, motility and morphology. Binds to activated (phosphorylated) protein-tyrosine kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane.

CIViC holds 3 clinical evidence items and 0 assertions across 3 variants, naming Vemurafenib. Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes clinical 0.67, affected pathway 0.86, literature 0.91, genetic association 0.00, somatic mutation 0.50).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: phosphoinositide-3-kinase regulatory subunit 2; Phosphatidylinositol 3-kinase regulatory subunit beta; P85B; p85; p85beta; p85-BETA
- Tags: cancer-genes-wave
- Symbol: PIK3R2
- Class: other
- Biology: Regulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signalling cascades involved in cell growth, survival, proliferation, motility and morphology. Binds to activated (phosphorylated) protein-tyrosine kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Indirectly regulates autophagy. Promotes nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement. Locus 19p13.11 (HGNC).
- Where found: Melanoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.67; CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:8980: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8980
- UniProt O00459: https://www.uniprot.org/uniprotkb/O00459/entry
- NCBI Gene 5296: https://www.ncbi.nlm.nih.gov/gene/5296
- Ensembl ENSG00000105647: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105647

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)

---
JSON: https://onco.cc/api/v1/entities/pik3r2.json